Uses of Getino B

Getino B medicine 300mg is prepared in the form of film-coated tablets, with the main ingredient being Tenofovir Disoproxil Fumarate. It is used to treat chronic hepatitis B or in combination with antiretroviral drugs to control HIV.

The active ingredient in Getino B is Tenofovir Disoproxil Fumarate. Getino B is indicated for use in the following cases:
In combination with at least 2 other antiretroviral drugs to control HIV in adults; Treatment of adult chronic hepatitis B in patients with compensated hepatitis (with evidence of viral replication, persistent elevation of ALT levels, histological evidence of anti-inflammatory activity and fibrosis) .

How to use: Take Getino B 300mg with food.
Dosage:
Dosage for adults: Treatment of chronic hepatitis B or HIV with a dose of 300mg (1 tablet)/day. Dosage for patients with chronic hepatitis B: So far, no optimal therapy has been found. Discontinuation of therapy should consider the following factors: HBeAg-positive patients without cirrhosis: Treatment should be initiated for at least 6-12 months after HBe seroconversion (HBeAg negative, HBV DNA negative with anti-HBe detection) determined or until HBs seroconversion becomes invalidated. Serum ALT and HBV DNA levels should be monitored regularly after discontinuation of therapy to detect viral recurrence. HBeAg-negative patients without cirrhosis should be treated at least until HBs seroconversion or signs of loss of efficacy appear. With treatment duration greater than 2 years, regular evaluation is recommended to determine appropriate maintenance therapy for the patient. Dosage for patients with renal impairment: For patients with mild renal impairment (creatinine clearance 50 - 80mL/min) no dose adjustment is required. At the same time, patients should regularly monitor serum creatinine and phosphorus clearance in patients with mild renal impairment. The recommended dose for patients is as follows: Creatin ≥ 50mL/min: The 300mg dose interval is every 24 hours. Creatin 30 - 49mL/min: The 300mg dose interval is every 48 hours. Creatin 10 - 29mL/min: The interval between doses of 300mg is every 72 - 96 hours. Hemodialysis: The interval between doses of 300 mg is every 7 days after dialysis or 12 hours after completion of dialysis. Creatin < 10 mL/min: There is no recommended dose.

Overdose: If an overdose of Getino B occurs, the patient should be monitored for signs of toxicity, if necessary, basic supportive treatment is needed. Tenofovir is eliminated by hemodialysis.
Missed dose: When you forget a dose of Getino B, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your usual dosing schedule.

When using Getino B, patients may experience some unwanted side effects:
Mild gastrointestinal effects: Diarrhea, vomiting, loss of appetite. Increased serum amylase levels, pancreatitis, hypophosphataemia, skin rash. Peripheral neuropathy, dizziness, headache, insomnia, depression, myalgia, weakness, sweating. Increased liver enzymes, increased blood triglyceride levels, hyperglycemia, neutrophil deficiency. Renal failure, Fanconi syndrome; Folic acidosis is often associated with hepatomegaly and steatosis, which is common when treated with nucleoside reverse transcriptase inhibitors. When experiencing side effects of Getino B, patients should stop taking the drug, notify their doctor or go to the nearest hospital.

Getino B is contraindicated for use in the following cases:
People with hypersensitivity to Tenofovir or its components. Do not use concurrently with other Tenofovir-containing drugs or Adefovir Dipivoxil. Do not give Getino B medicine to children under 18 years old.

Be careful when using Getino B:
People with lactic acidosis, severe hepatomegaly with steatosis, after treatment for severe hepatitis; People with lactic acidosis, severe hepatomegaly with steatosis including fatal cases when using Nucleoside analogues including Tenofovir Disoproxil Fumarate, when combined with other antiviral drugs; There have been cases of severe acute hepatitis in HBV-infected persons after discontinuation of anti-hepatitis B drug therapy (including Tenofovir Disoproxil Fumarate). Liver function should be monitored regularly, for at least several months, in patients who have stopped taking the drug. If appropriate, medication may be resumed. Temporarily discontinue Tenofovir Disoproxil Fumarate in patients with lactic acidosis or hepatotoxicity. Patients taking Tenofovir Disoproxil Fumarate or other antiretrovirals because opportunistic infections may develop, other complications of HIV infection. Therefore, it is necessary to monitor the patient's health carefully. Antiretroviral therapy, including Getino B, does not prevent sexual or blood transmission of HBV or HIV. Therefore, it is necessary to take appropriate protective measures. Getino B should not be used in patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption. When taking the drug in the elderly, bone abnormalities should be monitored because Tenofovir Disoproxil Fumarate can reduce bone density. Consideration should be given to creatinine clearance in patients with renal impairment prior to administration of Getino B. Patients at risk or with a history of renal dysfunction should be monitored regularly to detect changes in serum creatinine and phosphate. Cirrhotic patients may be at risk of hepatic decompensation in those with severe hepatitis, so their health should be closely monitored during treatment. Patients with HIV and hepatitis B co-infection: Persons with pre-existing liver dysfunction (including acute and chronic hepatitis) with an increase in liver function abnormalities during combination antiretroviral therapy should be carefully monitor. If there are signs of worsening liver health, the drug should be discontinued. Patients with dyslipidemia (subcutaneous fat loss, lipoma): Serum lipids and blood glucose should be tested. Patients with dyslipidemia should be appropriately managed. Appropriate regenerative syndrome: May be evaluated, and treated for anti-inflammatory symptoms as needed. Osteonecrosis: Patients should consult a doctor before taking the drug if they have ever had joint pain, stiffness, difficulty in movement. Using Getino B can cause dizziness, so drivers and machine operators need to be careful. Use caution when using Getino B in pregnant and lactating women, consult a doctor carefully.

Some drug interactions of Getino B:
Didanosine: Caution when using Tenofovir Disoproxil Fumarate with Didanosine simultaneously. Patients taking a 2-drug combination should be closely monitored for Didanosine-related side effects. Didanosine should be discontinued in patients with increased adverse events associated with this drug. Atazanavir: Tenofovir Disoproxil Fumarate may affect Atazanavir. Tenofovir Disoproxil Fumarate should only be used with enhanced Atazanavir. Nucleoside/Nucleotide triple therapy: High rate of viral failure, emergence of resistance in early stage HIV patients with daily tenofovir Disoproxil Fumarate in combination with Lamivudine and Abacavir, Lamivudine and Didanosine. Patients taking therapy 3, only Nucleoside should be carefully monitored health. Tacrolimus and Drugs Affecting Renal Function: Since Tacrolimus may affect renal function, the patient's health should be closely monitored when administered with Tenofovir Disoproxil Fumarate. Concomitant administration of Tenofovir Disoproxil Fumarate with drugs that reduce or compete for renal excretion may increase serum concentrations of Tenofovir Disoproxil Fumarate. HIV and HBV coinfection: Due to the risk of increased HIV resistance, in HIV/HBV coinfected patients Tenofovir Disoproxil Fumarate should only be used with antiretroviral therapy and with appropriate nutrition. When using Getino B, patients need to follow all doctor's advice to ensure high treatment efficiency, avoid the risk of overdose or unpredictable side effects.